Published in Blood on October 18, 2013
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med (2015) 1.04
Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice. J Immunol (2014) 1.02
EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion. Sci Rep (2015) 0.88
Regulation of T Cell Differentiation and Function by EZH2. Front Immunol (2016) 0.78
Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells. Transl Res (2014) 0.78
Regulatory T-Cell Therapy for Graft-versus-host Disease. J Immunol Res Ther (2016) 0.77
Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro. Exp Biol Med (Maywood) (2014) 0.77
Inhibition of EZH2 expression is associated with the proliferation, apoptosis and migration of SW620 colorectal cancer cells in vitro. Exp Biol Med (Maywood) (2015) 0.76
Epigenetic drug discovery: breaking through the immune barrier. Nat Rev Drug Discov (2016) 0.75
DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity. Cell Death Dis (2016) 0.75
The tumor microenvironment disarms CD8(+) T lymphocyte function via a miR-26a-EZH2 axis. Oncoimmunology (2016) 0.75
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol (2010) 11.80
Graft-versus-host disease. Lancet (2009) 8.78
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med (2003) 7.78
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol (2009) 5.72
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol (2002) 5.67
Maintaining the norm: T-cell homeostasis. Nat Rev Immunol (2002) 5.63
Graft-versus-host disease. Nat Rev Immunol (2007) 4.26
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood (2008) 3.85
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol (2012) 3.50
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell (2005) 3.01
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol (2001) 2.93
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood (2009) 2.91
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood (2001) 2.45
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci U S A (2004) 2.41
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest (2008) 2.23
Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol (2009) 2.08
Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood (2010) 2.04
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood (2010) 2.02
EZH2 and histone 3 trimethyl lysine 27 associated with Il4 and Il13 gene silencing in Th1 cells. J Biol Chem (2005) 1.93
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol (2013) 1.89
CD95, BIM and T cell homeostasis. Nat Rev Immunol (2009) 1.73
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood (2011) 1.67
Emerging roles for chromatin as a signal integration and storage platform. Nat Rev Mol Cell Biol (2013) 1.65
Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood (2009) 1.62
IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. Blood (2007) 1.59
Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol (2002) 1.48
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol (2006) 1.35
Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 1.27
Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood (2002) 1.23
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2010) 1.21
Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease. J Immunol (2005) 1.17
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. J Clin Invest (2009) 1.11
Unconventional association of the polycomb group proteins with cytokine genes in differentiated T helper cells. J Biol Chem (2008) 1.05
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Pharmacokinetics of the antiviral agent 3-deazaneplanocin A. Eur J Drug Metab Pharmacokinet (1996) 1.00
T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens. Transplantation (1994) 0.97
Mcl-1 antagonizes Bax/Bak to promote effector CD4(+) and CD8(+) T-cell responses. Cell Death Differ (2013) 0.95
Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant (2010) 0.88
Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol (2013) 0.86
Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy (2013) 0.81
Control of GVHD: it's in our DNA! Blood (2012) 0.80
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Galaxy: a platform for interactive large-scale genome analysis. Genome Res (2005) 35.75
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature (2010) 18.63
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol (2005) 12.70
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Histone demethylation by a family of JmjC domain-containing proteins. Nature (2005) 10.36
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Role of histone H3 lysine 27 methylation in X inactivation. Science (2003) 9.85
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol (2010) 9.35
Graft-versus-host disease. Lancet (2009) 8.78
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell (2004) 6.90
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med (2003) 6.81
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Hydrogen-bonded ferroelectrics based on metal-organic coordination. J Am Chem Soc (2009) 6.69
JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet (2006) 6.65
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature (2011) 6.48
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell (2005) 6.29
Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol (2007) 6.13
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
A framework for collaborative analysis of ENCODE data: making large-scale analyses biologist-friendly. Genome Res (2007) 5.97
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev (2003) 5.77
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
New nomenclature for chromatin-modifying enzymes. Cell (2007) 5.34
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep (2006) 5.19
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol (2006) 5.16
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature (2003) 5.04
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Supramolecular bola-like ferroelectric: 4-methoxyanilinium tetrafluoroborate-18-crown-6. J Am Chem Soc (2011) 4.73
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science (2010) 4.60
Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science (2006) 4.54
Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol Cell (2003) 4.49
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev (2011) 4.45
Integrative analysis of the cancer transcriptome. Nat Genet (2005) 4.44
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature (2005) 4.39
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
Diisopropylammonium chloride: a ferroelectric organic salt with a high phase transition temperature and practical utilization level of spontaneous polarization. Adv Mater (2011) 4.30
Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol (2008) 4.30
Expressed pseudogenes in the transcriptional landscape of human cancers. Cell (2012) 4.22
Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol (2013) 4.19
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science (2011) 4.12
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 4.10
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev (2011) 4.09
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet (2011) 4.04
Probabilistic model of the human protein-protein interaction network. Nat Biotechnol (2005) 3.99
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94